Morgensztern D, et al. - Given that a wide range of changes in tumor size is included in a partial response, according to the Response Evaluation Criteria in Solid Tumors, researchers investigated if further specification of tumor reduction according to depth of response (DpR) would afford a more exact relation to outcomes for patients with non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. Participants were NSCLC patients who have received carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel. These subjects were retrospectively analyzed. The link between DpR and overall survival (OS) was primarily assessed. Findings revealed a strong association of DpR with OS in this study sample.